On Monday, October 21, from 9 am to 4:30 pm ET, the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH) will host a joint public meeting entitled, “Advancing Smoking Cessation:  FDA and NIH Priorities.” The focus of the meeting is on advancing innovation of smoking cessation products to help both adults and youth.

The meeting will feature presentations and panel discussions on several smoking cessation-focused topics, including:

• Clinical and community perspectives
• Promising target areas for development
• Regulatory paths forward

The meeting will include an opportunity for public comment on several topics related to cessation.

The meeting is free and can be attended virtually or in-person at the FDA’s White Oak campus in Silver Spring, Maryland.  Additional information about the meeting, including specific questions for which public comment is being sought, is found in the Federal Register notice announcing the meeting.  Deadlines for registration, including for public comment, are as follows:

• In-person registration is required by October 15, 2024, while virtual registration is open through 9:00 am ET on the day of the meeting
• Registration to speak in-person during the public comment portion of the meeting is required by October 1 at 5 pm ET.  Please note that public comments during the meeting will only be accepted in person and not virtually.  Every effort will be made to accommodate as many speakers as possible; however, speaking spots are limited and not guaranteed.
• Written comments must be submitted by November 21, 2024, via the meeting’s public docket on regulations.gov (docket no. FDA-2024-N-4085).